1000’s of kids’s lives have been saved by a cost-free authorities initiative that expired final December. Congress must renew this program rapidly as a result of too many infants are dying needlessly.
Housed on the Meals and Drug Administration and totally funded by pharmaceutical firms for free of charge to taxpayers, the uncommon pediatric illness precedence overview voucher program affords a carrot to firms growing therapies for youngsters with uncommon and life-threatening ailments. Since so few children undergo from any single sickness, these medication hardly ever make sufficient cash to fund the extremely costly analysis underpinning them. So as a substitute of high-priced taxpayer-funded grants or subsidies, the federal government has one other solution to make up the shortfall. Corporations that efficiently convey a remedy for a uncommon pediatric illness to market get a voucher for a speedy FDA overview that can be utilized for a unique, unrelated drug. These vouchers can then be bought to different firms.
Since some medicines earn billions of {dollars} yearly, these certificates might be enormously useful to the enormous pharmaceutical firms that develop blockbuster medication to deal with adult-onset diseases. A precedence overview voucher lately bought for $150 million — sufficient to fund years of analysis. The vouchers are a sort of Robin Hood program by which large conglomerates give cash to tiny, cash-strapped biotechnology corporations to avoid wasting the world’s most susceptible sufferers.
This text is unique to STAT+ subscribers
Unlock this text — plus in-depth evaluation, newsletters, premium occasions, and information alerts.
Have already got an account? Log in
To learn the remainder of this story subscribe to STAT+.
